The Pulmonary Fibrosis Foundation (PFF) today announced the launch of its annual PFF Walk series, a nationwide effort to raise funds and awareness for pulmonary fibrosis (PF) and interstitial lung disease (ILD). More than 250,000 Americans are living with PF and ILD, progressive diseases that cause inflammation, scarring, or both, that damage the lung’s ability to absorb oxygen from the air.
In an effort to improve understanding of pulmonary fibrosis (PF) and interstitial lung disease (ILD), data from the PFF Registry is presenting researchers with opportunities to accelerate understanding of PF and ILD to improve patient outcomes.
The PFF celebrates and honors Black History Month this February. The PFF advocates for increasing diversity of patient representation through the PFF Community Registry to enhance research and improve treatment options for those in the African-American and other communities.
B. Smyth, 28, died on Nov. 17, 2022, after a long battle with pulmonary fibrosis, according to an Instagram post featuring his brother Denzil. Pulmonary fibrosis (PF) is a progressive, debilitating disease that causes scarring in the lungs and does not presently have a cure.
Findings provide the foundation for future therapeutic strategies by promoting repair of the pulmonary vascular system.
The Pulmonary Fibrosis Foundation (PFF) has developed new materials and tools for people living with pulmonary fibrosis (PF) to learn about and enroll in
clinical research studies.
The Pulmonary Fibrosis Foundation announced research results from four studies examining access to care and outcomes for patients living with pulmonary fibrosis and interstitial lung disease.
New Pulmonary Fibrosis Foundation (PFF) position statement advises that pulmonologists who treat patients with pulmonary fibrosis (PF) explore palliative care resources available in their communities to facilitate early referral and better quality of life.
The nationwide pulmonary fibrosis (PF) community will take a collective step forward to advance research, advocacy, and awareness in the Pulmonary Fibrosis Foundation’s (PFF) National Walk Day on Saturday, Sept. 25, during Pulmonary Fibrosis Awareness Month.
September is Pulmonary Fibrosis Awareness Month, presented by the Pulmonary Fibrosis Foundation (PFF) as a way to drive awareness of pulmonary fibrosis (PF), a debilitating, incurable lung disease. Learn more about the numerous endeavors intended to rejuvenate the fight against PF throughout September.
Toxicological Sciences delivers the latest toxicology research in the July 2021 issue. The issue features investigations in delivers the latest toxicology research in areas such as exposure to delta-9-tetrahydrocannabinol and cannabidiol, effects of ENDS vapors on amino acid metabolism, and more.
All Virtual Conference To Highlight PF Research And Quality Of Life Nov. 8-13
Site Features Resources and User-Friendly Tools for Patients
The Pulmonary Fibrosis Foundation (PFF) and Paradigm Medical Communications, LLC , have announced a collaborative partnership to design and implement a curriculum of continuing medical education (CME) activities in interstitial lung disease (ILD).
Kolb is research director at the Firestone Institute for Respiratory Health at McMaster and St. Joseph’s Healthcare Hamilton, as well as division director for respirology at the Department of Medicine. He is also the European Respiratory Journal’s chief editor.
To mark Clean Air Month, the Pulmonary Fibrosis Foundation (PFF) aims to increase public understanding of the role air pollution has in the development of interstitial lung diseases (ILD) such as pulmonary fibrosis (PF), including how polluted air can make you sick and the telltale signs to be aware of.
April 8, 2021 – The Division of Rheumatology, Department of Medicine, Faculty of Medicine (CU Medi), Chulalongkorn University and King Chulalongkorn Memorial Hospital, the Thai Red Cross Society (Chulalongkorn Hospital), in collaboration with the Departments of Hematology, Pulmonary and Critical Care Medicine, and Infectious diseases, held a press conference on “Thailand’s first successful treatment of systemic sclerosis patients with pulmonary fibrosis by stem cell transplantation“.
To mark Rare Disease Day on February 28, the Pulmonary Fibrosis Foundation (PFF) aims to increase public understanding of pulmonary fibrosis (PF) to drive home the importance of early diagnosis to help improve the quality of life for patients.
This National Donor Day (Feb. 14), the Pulmonary Fibrosis Foundation (PFF) honors lung donors for their life-saving contributions while celebrating the priceless impact that lung transplantation makes on the lives of those with diseases like pulmonary fibrosis (PF). More than…
According to the Surgeon General, 14% of Americans smoke and 16 million suffer from smoking-related diseases. Pulmonary fibrosis, a debilitating disease often caused by tobacco usage, is little-known among smokers. The Pulmonary Fibrosis Foundation shares insights on critical risk factors.
The Pulmonary Fibrosis Foundation (PFF) has announced United Therapeutics’ sponsorship of the PFF Registry, a research resource that tracks clinical data, blood samples and patient-reported outcomes from individuals living with pulmonary fibrosis nationwide.
Due to COVID-19, it’s important to talk to your doctor right away if you’re experiencing symptoms such as shortness of breath or cough. Take notes about your symptoms, so your doctor can pinpoint if they are early warning signs of another respiratory disease such as pulmonary fibrosis (PF).
The Pulmonary Fibrosis Foundation today announced the “Pinpoint PF” education and awareness campaign aimed at individuals with symptoms and at a higher risk for pulmonary fibrosis (PF).
October is Healthy Lung Month, an apt time to educate the public about the importance of protecting our lungs against mold, airborne pollutants and smoking – which put hundreds of thousands of Americans at higher risk for pulmonary fibrosis (PF).
Researchers have developed a technique that uses ultrasound to provide non-invasive assessments of pulmonary fibrosis and pulmonary edema. The technique has been shown to both quantify lung scarring and detect lung fluid in rats. A study on pulmonary edema in humans is under way.
September’s Pulmonary Fibrosis Awareness Month shares crucial realities and insights about the rare disease, its symptoms and helpful resources provided by the Pulmonary Fibrosis Foundation to educate the public about this devastating disease which impacts over 200,000 Americans.
Many reports have included pulmonary fibrosis as a potential consequence of COVID-19. Data shows some COVID-19 patients develop scarring on the lungs – but not necessarily chronic pulmonary fibrosis or interstitial lung disease, which are characterized by progressive scarring.